市场调查报告书
商品编码
1467762
2024-2032 年亨廷顿舞蹈症治疗市场报告(按类型、药物类型、年龄、配销通路、最终用户和地区)Huntington's Disease Treatment Market Report by Type, Drug Type, Age, Distribution Channel, End User, and Region 2024-2032 |
2023年全球IMARC Group舞蹈症治疗市场规模达4.911亿美元。亨廷顿舞蹈症发病率的上升、对该疾病治疗的先进药物的需求不断增加以及创新治疗方法的最新发展是推动市场的一些关键因素。
亨廷顿舞蹈症是指一种致命的神经退化性疾病,会导致大脑中的神经细胞进行性破坏。其症状包括各种运动、精神和认知障碍,如不自主抽搐、肌肉问题、组织和注意力困难、缺乏意识、失眠和社交退缩。亨廷顿氏症的治疗涉及多种药物的应用,例如抗精神病药、抗忧郁药、抗巴金森药和情绪稳定药。治疗过程还包括各种疗法,例如语言疗法、职业疗法、物理疗法和心理疗法。亨廷顿舞蹈症治疗有助于最大程度地减少运动和精神障碍的症状,帮助患者在更短的时间内适应新的能力,并制定应对策略。它还有助于改善日常任务、言语、保持姿势和平衡以及提高生活品质。
全球亨廷顿舞蹈症发生率的上升是推动市场成长的主要因素之一。亨廷顿舞蹈症治疗广泛用于抑制不自主的抽搐和扭动运动,治疗舞蹈症,减少暴力爆发和躁动,增强力量、灵活性、平衡性和协调性,从而改善生活品质并增强患者的能力执行日常任务,例如吃饭、通讯和行走。此外,对控制与亨廷顿舞蹈症相关的运动、认知和精神症状的先进药物的需求不断增加,也推动了市场的成长。与此一致的是,由于对该疾病及其根本原因的了解加深,新的疾病缓解药物的快速开发正在成为另一个生长诱导因素。此外,最近开发的创新治疗方法透过降低突变亨廷顿蛋白 (mTT) 的产生水平来阻止亨廷顿氏症的生长,对市场产生了积极影响。除此之外,使用反义寡核苷酸(ASO)靶向亨廷顿蛋白(HTT)信使核糖核酸(mRNA)及其整个中枢神经系统(CNS)蛋白质的反义技术的引入正在推动市场成长。此外,多个政府加大力度促进新药开发也有利于市场成长。其他因素,包括大众对亨廷顿病的认识不断提高、医疗保健行业的显着增长、研发(R&D)活动投资的增加、老年人口的增加以及对标籤外药物的需求不断增加,预计将推动市场的发展生长。
The global Huntington's disease treatment market size reached US$ 491.1 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,248.1 Million by 2032, exhibiting a growth rate (CAGR) of 17.9% during 2024-2032. The rising incidences of Huntington's disease, the increasing demand for advanced drugs for the disease treatment, and recent development of innovative therapeutic approaches represent some of the key factors driving the market.
Huntington's disease refers to a fatal neurodegenerative disorder that causes the progressive breakdown of nerve cells in the brain. Its symptoms include various movement, psychiatric, and cognitive impairments, such as involuntary jerking, muscle problems, difficulty in organizing and focusing, lack of awareness, insomnia, and social withdrawal. Huntington's disease treatment involves the application of various drugs, such as antipsychotics, antidepressants, antiparkinsonians, and mood-stabilizing drugs. The treatment process also includes various therapies, such as speech, occupational, physical, and psychotherapy. Huntington's disease treatment helps in minimizing the symptoms of movement and psychiatric disorders, assists patients in adapting to new abilities in a shorter time, and develops coping strategies. It also aids in improving everyday tasks, speech, maintaining posture and balance, and enhancing the quality of life.
The rising incidence of Huntington's disease across the globe is one of the primary factors driving the market growth. Huntington's disease treatment is widely used to suppress involuntary jerking and writhing movement, treat chorea, reduce violent outbursts and agitation, and enhance strength, flexibility, balance, and coordination, which, in turn, improves the quality of life and enhances the patient's ability to carry out daily routine tasks, such as eating, communications, and walking. Furthermore, the increasing demand for advanced drugs to control the motor, cognitive, and psychiatric symptoms associated with Huntington's disease is providing an impetus to the market growth. In line with this, the rapid development of new disease-modifying drugs owing to the improved understanding of the disease, and its underlying causes are acting as another growth-inducing factor. Additionally, the recent development of the innovative therapeutic approach that deters the growth of Huntington's disease by reducing mutant huntingtin (mTT) production levels is positively influencing the market. Apart from this, the introduction of antisense technology that uses antisense oligonucleotides (ASOs) to target huntingtin (HTT) messenger ribonucleic acid (mRNA) and its protein throughout the central nervous system (CNS) is propelling the market growth. Moreover, increasing initiatives by several governments to promote the development of novel drugs are favoring the market growth. Other factors, including rising awareness among the masses regarding Huntington's disease, significant growth in the healthcare industry, increasing investment in research and development (R&D) activities, rising geriatric population, and escalating demand for off-label medications, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global Huntington's disease treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, drug type, age, distribution channel, and end user.
Symptomatic Treatment
Disease-modifying Therapies
The report has also provided a detailed breakup and analysis of the Huntington's disease treatment market based on the type. This includes symptomatic treatment and disease-modifying therapies. According to the report, symptomatic treatment represented the largest segment.
Approved Drugs
Tetrabenazine
Deutetrabenazine
Off-label Drugs
A detailed breakup and analysis of the Huntington's disease treatment market based on the drug type has been provided in the report. This includes approved drugs (tetrabenazine and deutetrabenazine) and off-label drugs. According to the report, approved drugs accounted for the largest market share.
Below 50 Years
Above 50 Years
A detailed breakup and analysis of the Huntington's disease treatment market based on the age has been provided in the report. This includes below 50 years and above 50 years. According to the report, below 50 years accounted for the largest market share.
Drug Stores and Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
A detailed breakup and analysis of the Huntington's disease treatment market based on the distribution channel has been provided in the report. This includes drug store and retail, hospital, and online pharmacies. According to the report, drug store and retail pharmacies accounted for the largest market share.
Hospitals
Homecare
Specialty Clinics
Others
A detailed breakup and analysis of the Huntington's disease treatment market based on the end users has been provided in the report. This includes hospitals, homecare, specialty clinics, and others.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for Huntington's disease treatment. Some of the factors driving the North America Huntington's disease treatment market includes significant technological advancements, the rapid development of healthcare infrastructure, and the rising number of individuals suffering from Huntington's disease.
The report has also provided a comprehensive analysis of the competitive landscape in the global Huntington's disease treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AOP Health, Apotex Inc., Dr. Reddy's Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals PLC, Lupin Limited, Prilenia Therapeutics, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Vaccinex Inc. etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.